Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 25 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

16%

4 trials in Phase 3/4

Results Transparency

30%

3 of 10 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (12)
Early P 1 (1)
P 1 (2)
P 2 (3)
P 3 (2)
P 4 (2)

Trial Status

Completed10
Recruiting8
Unknown3
Not Yet Recruiting2
Withdrawn1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT02531893RecruitingPrimary

Psychological Treatments for Youth With Severe Irritability.

NCT07560072Not ApplicableNot Yet RecruitingPrimary

A Scalable Trans Diagnostic Intervention Targeting Adolescent Agency Supported by Conversational AI (AGENCIA)

NCT06484088Early Phase 1RecruitingPrimary

Study Brain Mechanisms of Frustration With Magnetoencephalography in Healthy Volunteers

NCT07544966Phase 4Not Yet Recruiting

Teen Vulnerability to Irritability: Brain and Estrogen Changes

NCT06871488Phase 4Recruiting

Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants

NCT07469215Not ApplicableRecruiting

Behavioral Parent Training With and Without AI Support for Children With Disruptive Behaviors

NCT07424781Not ApplicableRecruiting

Fluoxetine on Emotional Experience (FLEX) Study

NCT04654260Not ApplicableActive Not Recruiting

Behavior Therapy for Irritability in Autism

NCT06869928Not ApplicableRecruiting

Implementation of the Pain and Irritability of Unknown Origin (PIUO) Pathway in Community Pediatric Practices

NCT06814314Recruiting

AP Metabolism Transcriptomics

NCT04619862Phase 2Recruiting

Efficacy of Gabapentin in Treating Pain in Children With SNI (Gabapentin Trial)

NCT03464773Not ApplicableCompleted

Pain and Irritability in Non-Verbal Children

NCT03854019Phase 3Completed

Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease

NCT01965184Not ApplicableCompleted

Cognitive-Behavioral Therapy for Disruptive Behavior in Children and Adolescents

NCT02552147Phase 1Completed

Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism

NCT04632082Not ApplicableUnknown

Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19

NCT03238118Not ApplicableCompletedPrimary

Attention Bias Modification, Attention Control and Psychoeducation for Irritability in Children and Adolescents

NCT01375907Phase 1Completed

Safety Study of a Rotavirus Vaccine (Rotavin-M1) Among Healthy Adults

NCT01377571Phase 2Completed

A Dose-escalating Study to Evaluate the Immunogenicity and Safety of Rotavin-M1 Vaccine in Healthy Infants

NCT01942785Phase 3Completed

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

Scroll to load more

Research Network

Activity Timeline